Lutokhina Yulia, Seifatova Nasiba, Chernova Polina, Kireeva Natalia, Komarov Roman, Vukolova Marina, Pirozhkov Sergey, Yantikova Ekaterina, Babakulova Nargiza, Tlisov Boris, Dzyundzya Andrey, Volel Beatrice
Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), 119991 Moscow, Russian Federation.
Rev Cardiovasc Med. 2025 Apr 17;26(4):28234. doi: 10.31083/RCM28234. eCollection 2025 Apr.
Myocardial diseases such as myocarditis and cardiomyopathies are clinically important and can cause complications such as heart failure and arrhythmias, which increase the risk of death. The combination of myocarditis with cardiomyopathy is difficult to diagnose because their manifestations often overlap, and multiple myocardial diseases are usually not included in the diagnostic search. Hypertrophic cardiomyopathy (HCM) is the most common cardiomyopathy; however, few studies have examined the combination of myocarditis and HCM, thereby highlighting the importance of this problem. This article aimed to analyze the influence of myocarditis on clinical features and outcomes in patients with HCM.
A literature search was performed using PubMed and the Scientific Electronic Library eLIBRARY.ru databases. Relevant studies, published until November 2023, were analyzed in detail. Studies were selected in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards.
Twelve studies (three original articles and nine clinical cases) were isolated from a total cohort of 1504 publications and were included in the study. The prevalence of myocarditis in HCM ranged from 23.5% to 46.7%. The presence of concomitant myocarditis in patients with HCM was associated with heart failure progression, worsening of ventricular arrhythmias, and an increased risk of sudden cardiac death.
The incidence of myocarditis in HCM is high. Early detection and treatment of myocarditis in patients with HCM can slow the progression of heart failure rhythm disturbances and improve the disease prognosis.
The systematic review was registered in the International Prospective Register of Systematic Reviews PROSPERO (CRD42024499672, https://www.crd.york.ac.uk/PROSPERO/view/CRD42024499672).
心肌炎和心肌病等心肌疾病在临床上具有重要意义,可导致心力衰竭和心律失常等并发症,增加死亡风险。心肌炎与心肌病的合并情况难以诊断,因为它们的表现常常重叠,而且在诊断排查中通常不包括多种心肌疾病。肥厚型心肌病(HCM)是最常见的心肌病;然而,很少有研究探讨心肌炎与HCM的合并情况,从而凸显了这个问题的重要性。本文旨在分析心肌炎对HCM患者临床特征和预后的影响。
使用PubMed和科学电子图书馆eLIBRARY.ru数据库进行文献检索。对截至2023年11月发表的相关研究进行了详细分析。根据系统评价和Meta分析的首选报告项目(PRISMA)标准选择研究。
从总共1504篇出版物的队列中筛选出12项研究(3篇原创文章和9个临床病例)并纳入本研究。HCM中心肌炎的患病率在23.5%至46.7%之间。HCM患者合并心肌炎与心力衰竭进展、室性心律失常恶化以及心脏性猝死风险增加有关。
HCM中心肌炎的发病率很高。早期发现并治疗HCM患者的心肌炎可以减缓心力衰竭节律紊乱的进展,改善疾病预后。
PROSPERO注册情况:该系统评价已在国际前瞻性系统评价注册库PROSPERO中注册(CRD42024499672,https://www.crd.york.ac.uk/PROSPERO/view/CRD42024499672)。